Biospecifics Tech Cp (BSTC)

$88.53 0.00 (0.00%)

16:21 EST BSTC Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 638.68M

PE Ratio 54.31

EPS 1.63

Volume (Avg. Vol.)

Day's Range 88.53 - 88.53

52-Week Range 42.00 - 89.15

Dividend & Yield N/A (N/A)

BSTC Stock Predictions, Articles, and Biospecifics Tech Cp News

From the Web

SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Investors of Its Ongoing Merger Investigations; Shareholders are Encouraged to Contact the Firm – BSTC, UROV, CXO

From Halper Sadeh LLP Nov 18, 2020

NEW YORK, NY / ACCESSWIRE / November 18, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: BioSpecifics Technologies Corp. (NASDAQ:BSTC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Endo International plc for $88.50 per share. If you are a BioSpecifics shareholder, click on this link to learn more about your rights and

BioSpecifics Technologies (BSTC) Surpasses Q3 Earnings and Revenue Estimates

From Zacks Investment Research Nov 9, 2020

BioSpecifics (BSTC) delivered earnings and revenue surprises of 315.79% and 106.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Investors are Encouraged to Contact the Firm – BSTC, CBLI, PE, GLIBA

From Halper Sadeh LLP Nov 7, 2020

NEW YORK, NY / ACCESSWIRE / November 7, 2020 /Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: BioSpecifics Technologies Corp. (NASDAQ:BSTC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Endo International plc for $88.50 per share. If you are a BioSpecifics shareholder, click on this link to learn more about your rights and

Earnings Preview: BioSpecifics Technologies (BSTC) Q3 Earnings Expected to Decline

From Zacks Investment Research Nov 6, 2020

BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Endo (ENDP) Q3 Earnings & Sales Top Estimates, View Raised

From Zacks Investment Research Nov 6, 2020

Endo's (ENDP) earnings and sales beat estimates in the third quarter. The company raises its annual outlook.